#United States #New York #Class Action #Pomerantz #Altimmune

Class Action Alert: Altimmune, Inc.

Pomerantz Law Firm has put investors on notice regarding a class action lawsuit filed against Altimmune, Inc. (NASDAQ: ALT). The firm invites investors who have incurred losses to take action before the upcoming deadlines, which are critical for those who wish to be appointed as Lead Plaintiffs in the case. This move comes after serious allegations concerning the company's management and its potential engagement in securities fraud.

Background of the Case

The lawsuit centers on claims that Altimmune and its officers may have misled investors through deceptive practices regarding their financial standing and business operations. The company recently released data from the IMPACT Phase 2b MASH trial on Pemvidutide, which did not meet expectations. Despite prior indications of favorable results, it was revealed that the analysis did not demonstrate statistical significance concerning the primary endpoint of fibrosis reduction.

What's particularly alarming is that while initially there was a positive trend noted in the results, the placebo's response was higher than anticipated, undermining any assertions Altimmune made leading up to the announcement. During inquiries, company representatives appeared dismissive of concerns over the adverse results, attributing them to the preliminary nature of the trial and expressing hope for better outcomes in future testing phases.

Following this troubling news, Altimmune's stock plummeted by $4.10 per share, translating to a shocking 53.2% decrease, closing at $3.61 on June 26, 2025. This drastic decline triggered alarm bells among stakeholders and potential investors, highlighting the severity of the situation and prompting the ensuing class action lawsuit.

Call to Investors

Investors who purchased shares of Altimmune during the Class Period are encouraged to promptly reach out to Danielle Peyton at Pomerantz LLP. For those interested in participating or seeking more information about the class action, contacting Pomerantz via email at [email protected] is advisable. It's essential for potential plaintiffs to provide their contact details and the number of shares acquired to ensure they receive all necessary updates and documents, particularly the Complaint, which can be accessed via Pomerantz's official website.

As the deadline for appointing a Lead Plaintiff approaches on October 6, 2025, investors should act swiftly to protect their interests. This lawsuit not only aims to address the alleged misconduct by Altimmune but also serves as a reminder of the importance of transparency and accountability within publicly traded companies.

About Pomerantz LLP

With a legacy that spans over 85 years, Pomerantz LLP is acclaimed for its effective representation of clients in securities class actions. Founded by Abraham L. Pomerantz, recognized as a pioneer in the field, the firm has continually pursued justice for victims of fraud and corporate misconduct. Their extensive track record includes securing significant compensation for class members, solidifying their reputation as a leader among law firms handling corporate and antitrust litigation.

For further information about joining the class action, interested individuals can visit www.pomerantzlaw.com. It’s crucial for investors to stay informed on this evolving case as more developments arise. 📈

Attorney advertising. Past results do not guarantee similar outcomes.